Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04246047 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 3
- Development phase
- 494
- Enrollment target
- 20
- Study locations
NCT04246047 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 494 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04246047, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 494 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Bortezomib
Study Locations (20)
New South Wales
- GSK Investigational Site - Camperdown
- GSK Investigational Site - Liverpool
- GSK Investigational Site - St Leonards
- GSK Investigational Site - Waratah
- GSK Investigational Site - Wollongong
Victoria
- GSK Investigational Site - Box Hill
- GSK Investigational Site - Heidelberg
- GSK Investigational Site - Melbourne
Queensland
- GSK Investigational Site - Benowa
- GSK Investigational Site - Herston
Western Australia
- GSK Investigational Site - Murdoch
- GSK Investigational Site - Nedlands
Arizona
- GSK Investigational Site - Yuma
Colorado
- GSK Investigational Site - Denver
Connecticut
- GSK Investigational Site - Fairfield
Kansas
- GSK Investigational Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2020-05-07 |
| Est. Completion | 2026-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04246047
The ClinicalTrials.gov registry entry for NCT04246047 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (10% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Belantamab mafodotin is the first listed.
NCT04246047 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New South Wales, Victoria, Queensland.
Frequently Asked Questions
What is clinical trial NCT04246047 about?
NCT04246047 is a clinical study titled "Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma". This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
What is the current status of trial NCT04246047?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 494 participants. The study started on 2020-05-07. Estimated completion is 2026-06-19.
What conditions does trial NCT04246047 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04246047?
The interventions under investigation include: Belantamab mafodotin (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04246047?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04246047 being conducted?
This trial has 20 study locations across Arizona, Colorado, Connecticut, Kansas, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.